Generic Name and Formulations:
Cyclopentolate HCl 0.5%, 1%, 2%; oph soln; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for CYCLOGYL:
To produce mydriasis and cycloplegia.
Instill 1 or 2 drops of 0.5%, 1%, or 2% in the eye; may repeat in 5–10 minutes if necessary. Apply digital pressure to lacrimal sac for 2–3 minutes after instillation to reduce systemic absorption.
Small infants: instill 1 drop of 0.5% in the eye; apply pressure over nasolacrimal sac for 2–3 minutes, observe closely for 30 minutes. Children: instill 1 or 2 drops of 0.5%, 1%, or 2% in the eye; may repeat 5–10 minutes later with 0.5% or 1% solution if necessary; apply digital pressure to lacrimal sac for 2–3 minutes after instillation to reduce systemic absorption.
Untreated narrow-angle glaucoma or when untreated anatomically narrow angles are present.
Down's syndrome. Angle-closure glaucoma. Feeding intolerance in infants; withhold feeding for 4 hours after examination. Pregnancy (Cat.C). Nursing mothers.
May interfere with antihypertensive action of carbachol, pilocarpine, ophthalmic cholinesterase inhibitors.
Ocular effects (eg, increased intraocular pressure, burning, photophobia, blurred vision, irritation, hyperemia, conjunctivitis, blepharoconjunctivitis, punctate keratitis, synechiae); CNS disturbances (esp. in children).
Soln 0.5%—15mL; 1%, 2%—2mL, 5mL, 15mL
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Romosozumab: Effective in Men With Osteoporosis
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- NT-proBNP May Predict Cardiovascular Outcomes in Type 2 Diabetes
- Placebo Effect of Various Female Sexual Dysfunction Drug Txs Assessed
- Link Between Oral Diabetes Medications and Bullous Pemphigoid
- Calcium Channel Blocker May Benefit Patients With Type 1 Diabetes
- β-Cell Function in Youth With Impaired Glucose Tolerance, T2D